Author: Spirollari, Eris ; McGoldrick, Patricia ; Al-Mufti, Fawaz ; Nuoman, Rolla ; Clare, Kevin ; Overby, Philip ; Wolf, Steven ; Thaker, Akash ; Vazquez, Sima ; Nolan, Bridget

(1) Background: Celiac disease (CD) can cause long-term inflammation and endothelial dysfunction and has been cited as a risk factor for acute ischemic stroke (AIS) in pediatric patients. However, the rate and outcomes of AIS in pediatric patients with CD has not been explored in a large population. Our objective is to explore the rate, severity, and outcomes of CD amongst pediatric AIS patients on a nationwide level. (2) Methods: The National Inpatient Sample (NIS) database was queried from 2016 to 2020 for pediatric patients with a principal diagnosis of AIS. Patients with a concurrent diagnosis of CD (AIS-CD) were compared to those without (AIS). Baseline demographics and comorbidities, clinical variables of severity, hospital complications, and the rates of tissue plasminogen activator (tPA) and mechanical thrombectomy were compared between the two groups. The main outcomes studied were mortality, discharge disposition, length of stay (LOS), and total hospital charges. (3) Results: Of 12,755 pediatric patients with a principal diagnosis of AIS, 75 (0.6%) had concurrent CD. There were no differences in the severity, discharge disposition, or mortality between the AIS-CD and AIS patients. Patients with AIS-CD were more likely to receive tPA at an outside hospital within 24 h of admission (p < 0.01) and more likely to undergo mechanical thrombectomy (p < 0.01) compared to the AIS patients. (4) Conclusions: CD patients made up only 0.6% of all pediatric AIS patients. No differences in the severity, mortality, or discharge disposition suggests a minimal to absent role of CD in the etiology of stroke. The CD-AIS patients were more likely to receive a tPA or undergo a mechanical thrombectomy; studies are needed to confirm the safety and efficacy of these interventions in pediatric patients.

01 Jun 2023·Pediatric neurology

Responsive Neurostimulation in Drug-Resistant Pediatric Epilepsy: Findings From the Epilepsy Surgery Subgroup of the Pediatric Epilepsy Research Consortium

Article

Author: Karia, Samir ; Shrey, Daniel ; Tatachar, Priyamvada ; Wolf, Steven ; Eschbach, Krista ; Samanta, Debopam ; Singh, Rani K ; Karakas, Cemal ; Manuel, Chad M ; McCormack, Michael J ; Auguste, Kurtis I ; Ostendorf, Adam ; Depositario-Cabacar, Dewi ; Gonzalez-Giraldo, Ernesto ; Wong-Kisiel, Lily ; Perry, M Scott ; Liu, Gang ; Alexander, Allyson L ; Numis, Adam L ; Olaya, Joffre ; Reddy, Shilpa B

BACKGROUND:

Responsive neurostimulation (RNS), a closed-loop intracranial electrical stimulation system, is a palliative surgical option for patients with drug-resistant epilepsy (DRE). RNS is approved by the US Food and Drug Administration for patients aged ≥18 years with pharmacoresistant partial seizures. The published experience of RNS in children is limited.

METHODS:

This is a combined prospective and retrospective study of patients aged ≤18 years undergoing RNS placement. Patients were identified from the multicenter Pediatric Epilepsy Research Consortium Surgery Registry from January 2018 to December 2021, and additional data relevant to this study were retrospectively collected and analyzed.

RESULTS:

Fifty-six patients received RNS during the study period. The mean age at implantation was 14.9 years; the mean duration of epilepsy, 8.1 years; and the mean number of previously trialed antiseizure medications, 4.2. Five patients (9%) previously trialed dietary therapy, and 19 patients (34%) underwent prior surgery. Most patients (70%) underwent invasive electroencephalography evaluation before RNS implantation. Complications occurred in three patients (5.3%) including malpositioned leads or transient weakness. Follow-up (mean 11.7 months) was available for 55 patients (one lost), and four were seizure-free with RNS off. Outcome analysis of stimulation efficacy was available for 51 patients: 33 patients (65%) were responders (≥50% reduction in seizure frequency), including five patients (10%) who were seizure free at follow-up.

CONCLUSIONS:

For young patients with focal DRE who are not candidates for surgical resection, neuromodulation should be considered. Although RNS is off-label for patients aged <18 years, this multicenter study suggests that it is a safe and effective palliative option for children with focal DRE.

01 Jun 2023·Pediatric allergy, immunology, and pulmonology

Changes in Body Mass Index in Children and Adolescents with Asthma during the COVID-19 Pandemic.

Article

Author: Kim, Christy ; Dozor, Allen J ; Desantis, Samuel ; Welter, John J ; Fan, Kathleen ; Lindsay-Adler, Diane ; Krishnan, Sankaran ; Krishnan, Sheila V ; Kim, Jennifer

Background: Increased weight gain in children during the COVID-19 pandemic has been reported. Changes in weight in children with asthma during this period have not been well described. Methods: Retrospective review of children with asthma, 6-18 years of age, seen in 2019 and 2020. Mean monthly rates of change in body mass index (BMI) were compared between years. Demographic and asthma-related factors were examined. Results: Two hundred sixty-seven patients were enrolled. BMI increased by 0.128 ± 0.283 kg/m²/month during the pandemic year as compared with 0.084 ± 0.160 kg/m²/month during the previous year (P = 0.03). Patients with baseline overweight or obesity trended toward higher rates of BMI increase than those starting with normal weight, with the greatest BMI increase occurring in the severely obese. Conclusions: In this single-site study of children with asthma, there was a greater monthly rate of BMI gain during the early pandemic as compared with that observed in the previous year.

News (Medical) associated with BOSTON CHILDREN'S HEALTH PHYSICIANS, LLP

20 Jun 2023

·www.prnewswire.com

Boston Children's Health Physicians Opens New Administrative Headquarters

WESTCHESTER, N.Y., June 20, 2023 /PRNewswire/ -- Boston Children's Health Physicians (BCHP) celebrated the opening of its new administrative headquarters located at 400 Columbus Avenue, Suite 200E, Valhalla NY, with a ribbon-cutting ceremony on April 25, 2023. The event was attended by BCHP's founders, representatives from Boston Children's Hospital, senior executives, leaders in the medical field, and staff who gathered to mark the occasion and recognize the significance of this new facility for the organization. This office has been built exclusively for BCHP, with the aim of providing a modern and efficient space for the organization's administrative staff to work together. "Our new headquarters will create a collaborative work environment for our administrative staff, increasing job satisfaction. This, in turn, can help us continue to attract and retain a dedicated workforce that is committed to providing the highest quality of care to our patients. We believe that this transition will ultimately benefit our patients by ensuring they receive consistent, high-quality care from a team of devoted professionals," said Allen J. Dozor, MD, President. Gerard Villucci, Chief Executive Officer, added, "This new administrative headquarters location is a significant investment in the future of BCHP. By consolidating our administrative functions in one location, we can more effectively manage resources and reduce costs, allowing us to focus on what we do best - providing high-quality pediatric care to the children in our region." The benefits of having the administrative staff of a comprehensive healthcare group working under one roof are numerous. It enables faster decision-making, improved communication, and better collaboration, leading to improved patient care and outcomes. BCHP is excited to move forward with this new administrative headquarters location, and looks forward to continuing to provide outstanding pediatric care to its patients. For more information about BCHP and its services, please visit bchphysicians.org. About Boston Children's Health Physicians Boston Children's Health Physicians (BCHP) is a large multi-specialty group with more than 300 clinicians. BCHP proudly offer a full range of care to families in over 55 practices throughout New York's Metropolitan Area, the Hudson Valley and Connecticut. Working with partners at Maria Fareri Children's Hospital at WMCHealth and New York Medical College, BCHP is dedicated to state-of-the-art patient care, excellence in medical education, and cutting-edge scientific research. BCHP is also part of the Boston Children's Hospital network of care, the #1-ranked children's hospital by U.S.News & World Report. For more, visit our website and follow us on Facebook @BCHPhysicians. CONTACT: Kristen DiBari, Boston Children's Health Physicians 914-614-4227 | [email protected] SOURCE Boston Children's Health Physicians

100 Deals associated with BOSTON CHILDREN'S HEALTH PHYSICIANS, LLP

100 Translational Medicine associated with BOSTON CHILDREN'S HEALTH PHYSICIANS, LLP

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 26 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

PR1P ( VEGF )	Colitis, Ulcerative More	Preclinical
CD161 mAb(Boston Children's Hospital) ( CD161 )	Hematologic Neoplasms More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis